Bristol-Myers Squibb Company announced that belatacept, an investigational co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of nine company-sponsored clinical presentations at the upcoming American Transplant Congress to be held May 30 to June 3 in Boston. Belatacept is in phase-III development.

"Bristol-Myers Squibb is committed to developing innovative therapies to address significant unmet medical needs," said Elliott Sigal, executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "We are pleased to share our belatacept phase-III data for the first time at an important scientific conference for transplant professionals."